{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["COVID-19", "Meta-analysis", "Mortality", "Ozone"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "36513208", "DateCompleted": {"Year": "2023", "Month": "02", "Day": "07"}, "DateRevised": {"Year": "2023", "Month": "04", "Day": "13"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2022", "Month": "12", "Day": "10"}], "ELocationID": ["10.1016/j.ctim.2022.102907", "S0965-2299(22)00110-8"], "Journal": {"ISSN": "1873-6963", "JournalIssue": {"Volume": "72", "PubDate": {"Year": "2023", "Month": "Mar"}}, "Title": "Complementary therapies in medicine", "ISOAbbreviation": "Complement Ther Med"}, "ArticleTitle": "Benefits of ozone on mortality in patients with COVID-19: A systematic review and meta-analysis.", "Pagination": {"StartPage": "102907", "MedlinePgn": "102907"}, "Abstract": {"AbstractText": ["The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. Ozone therapy has long been used in the treatment of a variety of infectious diseases, probably through its antioxidant properties and the supply of oxygen to hypoxic tissues. This systematic review and meta-analysis aimed to determine the efficacy of ozone on mortality in patients with COVID-19.", "A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Prospective controlled trials on treatment of COVID-19 with ozone, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs) and weighted mean differences (WMDs), with 95% confidence intervals (CIs).", "Eight trials (enrolling 371 participants) met the inclusion criteria. Ozone therapy showed significant effects on mortality (RR 0.38, 95% CI 0.17-0.85; P\u00a0=\u00a00.02), length of hospital stay (WMD -1.63 days, 95% CI -3.05 to -0.22 days; P\u00a0=\u00a00.02), and polymerase chain reaction (PCR) positivity (RR 0.07, 95% CI 0.01-0.34; P\u00a0=\u00a00.001).", "Ozone therapy significantly reduced mortality, PCR positivity, and length of stay in hospitalized patients with COVID-19. Ozone therapy should be considered for COVID-19 patients."], "CopyrightInformation": "Copyright \u00a9 2022 The Authors. Published by Elsevier Ltd.. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China."}], "LastName": "Shang", "ForeName": "Wenli", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China."}], "LastName": "Wang", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China."}], "LastName": "Wang", "ForeName": "Guizuo", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China. Electronic address: sesory@yeah.net."}], "LastName": "Han", "ForeName": "Dong", "Initials": "D"}], "PublicationTypeList": ["Meta-Analysis", "Systematic Review", "Journal Article"]}, "MedlineJournalInfo": {"Country": "Scotland", "MedlineTA": "Complement Ther Med", "NlmUniqueID": "9308777", "ISSNLinking": "0965-2299"}, "ChemicalList": [{"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}, {"QualifierName": [], "DescriptorName": "Antioxidants"}], "CoiStatement": "Conflict of interest None of the authors has a conflict of interest to declare."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Qin J., Wang G., Han D. Benefits of plasma exchange on mortality in patients with COVID-19: a systematic review and meta-analysis. Int J Infect Dis IJID Publ Int Soc Infect Dis. 2022;122:332\u2013336.", "ArticleIdList": ["PMC9192121", "35709964"]}, {"Citation": "Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782\u2013793.", "ArticleIdList": ["32648899"]}, {"Citation": "Rowen R.J. Ozone and oxidation therapies as a solution to the emerging crisis in infectious disease management: a review of current knowledge and experience. Med Gas Res. 2019;9:232\u2013237.", "ArticleIdList": ["PMC7802416", "31898609"]}, {"Citation": "Valdenassi L., Franzini M., Ricevuti G., Rinaldi L., Galoforo A.C., Tirelli U. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19. Eur Rev Med Pharmacol Sci. 2020;24 4059-61.", "ArticleIdList": ["32374009"]}, {"Citation": "\u00c7olak \u015e., Gen\u00e7 Yavuz B., Yavuz M., et al. Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19. Int J Clin Pract. 2021;75", "ArticleIdList": ["PMC8236993", "33971067"]}, {"Citation": "Mart\u00ednez-S\u00e1nchez G., Schwartz A., Donna V.D. Potential cytoprotective activity of ozone therapy in SARS-CoV-2/COVID-19. Antioxidants. 2020:9.", "ArticleIdList": ["PMC7278582", "32384798"]}, {"Citation": "Clavo B., P\u00e9rez J.L., L\u00f3pez L., et al. Effect of ozone therapy on muscle oxygenation. J Altern Complement Med. 2003;9:251\u2013256.", "ArticleIdList": ["12804078"]}, {"Citation": "Zheng Z., Dong M., Hu K. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19. J Med Virol. 2020;92 2348-50.", "ArticleIdList": ["PMC7280732", "32437014"]}, {"Citation": "Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(264\u20139):W64.", "ArticleIdList": ["19622511"]}, {"Citation": "Detsky A.S., Naylor C.D., O'Rourke K., McGeer A.J., L'Abb\u00e9 K.A. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol. 1992;45:255\u2013265.", "ArticleIdList": ["1569422"]}, {"Citation": "Shang W., Wang G., Wang Y., Han D. The safety of long-term use of inhaled corticosteroids in patients with asthma: a systematic review and meta-analysis. Clin Immunol. 2022;236", "ArticleIdList": ["35218965"]}, {"Citation": "Qin J., Wang G., Han D. Benefits of LAMA in patients with asthma-COPD overlap: a systematic review and meta-analysis. Clin Immunol. 2022;237", "ArticleIdList": ["35346865"]}, {"Citation": "Shang W., Zhang Y., Liu L., Chen F., Wang G., Han D. Benefits of continuous positive airway pressure on blood pressure in patients with hypertension and obstructive sleep apnea: a meta-analysis. Hypertens Res Off J Jpn Soc Hypertens. 2022", "ArticleIdList": ["35701490"]}, {"Citation": "Higgins J.P., Altman D.G., G\u00f8tzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ Clin Res Ed. 2011;343:d5928.", "ArticleIdList": ["PMC3196245", "22008217"]}, {"Citation": "Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u2013605.", "ArticleIdList": ["20652370"]}, {"Citation": "Shang W., Zhang Y., Han D. Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: a meta-analysis. Clin Cardiol. 2022", "ArticleIdList": ["PMC9574714", "35916355"]}, {"Citation": "Qin J., Wang G., Han D. Selexipag in patients with pulmonary hypertension: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2022", "ArticleIdList": ["36283497"]}, {"Citation": "Guyatt G., Oxman A.D., Akl E.A., et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u2013394.", "ArticleIdList": ["21195583"]}, {"Citation": "Araimo F., Imperiale C., Tordiglione P., et al. Ozone as adjuvant support in the treatment of COVID-19: a preliminary report of probiozovid trial. J Med Virol. 2021;93 2210-20.", "ArticleIdList": ["33111980"]}, {"Citation": "Dengiz E., \u00d6zcan \u00c7., G\u00fcven Y., et al. Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial. Med Gas Res. 2022;12:55\u201359.", "ArticleIdList": ["PMC8562398", "34677153"]}, {"Citation": "Fern\u00e1ndez-Cuadros M.E., Albaladejo-Flor\u00edn M.J., \u00c1lava-Rabasa S., et al. Compassionate use of rectal ozone (O(3)) in severe COVID-19 pneumonia: a case-control study. SN Compr Clin Med. 2021:1\u201315.", "ArticleIdList": ["PMC7984736", "33778374"]}, {"Citation": "Hern\u00e1ndez A., Vi\u00f1als M., Pablos A., et al. Ozone therapy for patients with COVID-19 pneumonia: preliminary report of a prospective case-control study. Int Immunopharmacol. 2021;90", "ArticleIdList": ["PMC7833586", "33310665"]}, {"Citation": "Shah M., Captain J., Vaidya V., et al. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: a phase 1/11 randomized control trial (SEOT study) Int Immunopharmacol. 2021;91", "ArticleIdList": ["PMC7758022", "33421928"]}, {"Citation": "Sozio E., De Monte A., Sermann G., et al. CORonavirus-19 mild to moderate pneumonia management with blood ozonization in patients with respiratory failure (CORMOR) multicentric prospective randomized clinical trial. Int Immunopharmacol. 2021;98", "ArticleIdList": ["PMC8196321", "34186281"]}, {"Citation": "Tascini C., Sermann G., Pagotto A., et al. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. Intern Emerg Med. 2021;16 669-75.", "ArticleIdList": ["PMC7603641", "33131033"]}, {"Citation": "Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395 507-13.", "ArticleIdList": ["PMC7135076", "32007143"]}, {"Citation": "Elvis A.M., Ekta J.S. Ozone therapy: a clinical review. J Nat Sci Biol Med. 2011;2:66\u201370.", "ArticleIdList": ["PMC3312702", "22470237"]}, {"Citation": "Cattel F., Giordano S., Bertiond C., et al. Ozone therapy in COVID-19: A narrative review. Virus Res. 2021;291", "ArticleIdList": ["PMC7585733", "33115670"]}, {"Citation": "Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65\u2013W94.", "ArticleIdList": ["19622512"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "9", "Day": "8"}, {"Year": "2022", "Month": "12", "Day": "5"}, {"Year": "2022", "Month": "12", "Day": "9"}, {"Year": "2022", "Month": "12", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "12", "Day": "13", "Hour": "19", "Minute": "24"}, {"Year": "2022", "Month": "12", "Day": "10"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36513208", "PMC9737514", "10.1016/j.ctim.2022.102907", "S0965-2299(22)00110-8"]}}], "PubmedBookArticle": []}